Trials / Unknown
UnknownNCT03628521
First-line Combination Treatment Based on Anlotinib
Anlotinib-based Combination as First-line Treatment in Advanced Non-small Cell Lung Cancer: a Single Center, Three Arms and Exploratory Study
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Shanghai Chest Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to explore safety and therapeutic efficacy of anlotinib combined with erlotinib/chemotherapy/IBI308 as first-line treatment in advanced NSCLC patients. The primary endpoints of the study are safety and objective response rate (ORR);the secondary endpoints are disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin | Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice |
Timeline
- Start date
- 2018-07-20
- Primary completion
- 2019-12-31
- Completion
- 2020-12-31
- First posted
- 2018-08-14
- Last updated
- 2018-08-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03628521. Inclusion in this directory is not an endorsement.